ZYME - Zymeworks Announces New Director Nominee | Benzinga
VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company's upcoming annual general meeting of stockholders to be held on December 7, 2023.
"As the Company continues to execute on our strategy to support the approval and commercialization of zanidatamab while targeting five IND filings for new product candidates before the end of 2027, we are pleased to announce a significant proposed addition to our board of directors. With two prior additions to our board of directors already during 2023, these changes help secure the diversity of leadership experience required to successfully achieve our growth ambition over the next several years and beyond," stated Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "With this in mind, we are delighted to invite Dr. Davidson to join our board of directors. Dr. Davidson's substantial expertise in the field of oncology and foundational work in advancing insights in cancer biology from the bench through clinical studies and into the patient community arrives at a crucial time as we prepare for pivotal milestones in our product pipeline."
"I am excited to be nominated to join the Zymeworks board of directors, and deeply share in its patient-centered mission and commitment to improving the standard of care for difficult-to-treat cancers," stated Dr. Nancy Davidson, MD. "I look forward to using my clinical experience to contribute to the development of data-driven and differentiated next-generation therapies for patients with inadequate treatment options."
Dr. Davidson is an oncologist and researcher who is a top opinion leader in the field of breast cancer biology and treatment, with a particular interest in developing evidence-based clinical pathways in breast cancer treatment. She has contributed foundational research to the understanding of how hormones affect gene expression and cell growth in breast cancer, and how hormonal deprivation and other therapies trigger breast cancer cells to kill themselves through apoptosis, or programmed cell death. Her lab studies have paved the way for new clinical trials of drugs that exploit these pathways to kill breast cancer. She has also led several critical clinical trials that have advanced the care of breast cancer patients ...